MARKET COMPOSITE
ALKS - Alkermes plc8:00:00 PM 3/28/2024
Price
$27.07
-0.18 (-0.66%)
Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies , the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio. Alkermes has more than 20 commercial drug products and candidates that address serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are primary to the company: risperidone long-acting Injection for schizophrenia and bipolar 1 disorder, paliperidone palmitate for schizophrenia, 4-aminopyridine to improve walking in patients with multiple sclerosis, naltrexone for extended-release injectable suspension for alcohol and opioid dependence, and exenatide extended-release for injectable suspension for the treatment of type 2 diabetes. Bydureon is a once-weekly, extended-release form of the drug, exenatide , and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. It is approved in Europe and the U.S.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue377.5MM-1%
Gross Profit307.4MM-
Cost Of Revenue70.1MM+14%
Operating Income178.6MM-
Operating Expenses128.8MM-
Net Income112.8MM-
R&D-20.8MM-121%
G&A140.6MM-17%
Amortization9MM+0%
Interest Expense6.1MM+1%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news